Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study

Eur J Ophthalmol. Jul-Sep 1992;2(3):144-9.

Abstract

135 patients were entered into a 28-day randomized double-masked multicentre study comparing the efficacy and short-term safety of lodoxamide 0.1% ophthalmic solution (Alomide--Alcon Laboratories), a mast cell stabilizer, with sodium cromoglycate 2% ophthalmic solution (Opticrom--Fisons Pharmaceuticals) in the treatment of allergic eye disease. Patients given lodoxamide 0.1% showed a significantly more rapid and greater improvement in their signs and symptoms of allergic eye disease than patients given sodium cromoglycate 2%. Both treatments were found to be safe, and side-effect profiles were comparable between the two treatment groups, although the overall incidence of side-effects in this study was found to be less frequent in the lodoxamide-treated group.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Conjunctivitis, Allergic / drug therapy*
  • Cromolyn Sodium / adverse effects
  • Cromolyn Sodium / therapeutic use*
  • Double-Blind Method
  • Drug Tolerance
  • Female
  • Humans
  • Male
  • Middle Aged
  • Ophthalmic Solutions / therapeutic use
  • Oxamic Acid / administration & dosage
  • Oxamic Acid / analogs & derivatives*
  • Oxamic Acid / therapeutic use

Substances

  • Ophthalmic Solutions
  • Cromolyn Sodium
  • Oxamic Acid
  • lodoxamide ethyl